News | June 02, 2008

First GE Discovery VCT PET/CT Installed in Children's Hospital

June 3, 2008 - Seattle Children's Hospital is the first pediatric facility to install a 64-slice GE Discovery VCT PET/CT, combining the system with tailored pediatric imaging protocols to allow Children�s radiologists to best meet the needs of its pediatric patients by more accurately diagnosing conditions and pinpointing treatment areas, while protecting children from excessive diagnostic radiation exposure.

The Discovery VCT PET/CT scanner pairs Positron Emission Tomography (PET) with Computed Tomography (CT) and takes 64 pictures of the tumor site that are combined into a comprehensive 3D image allowing radiologists to determine the presence of disease, pinpoint specific biopsy sites and accurately monitor the effects of treatment.

The Discovery VCT PET/CT is most commonly used in oncology to diagnose lymphoma, neuroblastoma, brain tumors, sarcomas and thyroid cancer. Additionally, it can also assist in the diagnosis of myocardial viability, ischemia, coronary artery disease and in localizing epilepsy and seizure origin.

Diagnostic imaging with a PET/CT scanner requires a small amount of radiation. Studies have shown that these small amounts of radiation can slightly increase the risk of adverse health effects. At Seattle Children�s Hospital, PET/CT scans are designed to minimize diagnostic radiation while ensuring image quality. The scans are only performed when the benefit far outweighs the risk of adverse effects.

The PET scan is a metabolic imaging technology that detects changes in cell energy to establish whether tumors are active or inactive. The PET scan also determines if tumors have spread locally, or to outlying locations away from the primary tumor. The CT scan is then used to precisely identify the location of these cells within the childn's body.

For more information: www.gehealthcare.com, www.seattlechildrens.org

Related Content

Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...